Astellas Pharma (Netherlands)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Astellas Pharma (United States)美国3
2. RTI Health Solutions美国2
3. University of Southern Denmark丹麦2
4. Humana (United States)美国2
5. Karolinska Institutet瑞典2
6. Gilead Sciences (United Kingdom)英国1
7. GlaxoSmithKline (Belgium)比利时1
8. Gilead Sciences (United States)美国1

按月发文

逐年被引

最新文献

1. 1
   Navigating Non-interventional Post-authorization Studies in East Asia: Regulatory Challenges, Opportunities, and Future DirectionsDrug Safety20250
2. 2
   Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study programPharmacoepidemiology and Drug Safety20240
3. 3
   Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort StudyDrug Safety202125
4. 4
   Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United KingdomPharmacoepidemiology and Drug Safety202030
5. 5
   A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit–Risk Assessment of MedicinesDrug Safety20155

高被引文献

1. 1
   Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United KingdomPharmacoepidemiology and Drug Safety202030
2. 2
   Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort StudyDrug Safety202125
3. 3
   A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit–Risk Assessment of MedicinesDrug Safety20155

主要发表期刊